Lenvatinib in the therapy of thyroid cancer:A single institutional experience

DOI
  • YAMAUCHI Moriyasu
    Department of Otolaryngology-Head & Neck Surgery, Saga University Faculty of Medicine
  • MINESAKI Akimichi
    Department of Otolaryngology-Head & Neck Surgery, Saga University Faculty of Medicine
  • SATO Yuki
    Department of Otolaryngology-Head & Neck Surgery, Saga University Faculty of Medicine
  • KURATOMI Yuichiro
    Department of Otolaryngology-Head & Neck Surgery, Saga University Faculty of Medicine

Bibliographic Information

Other Title
  • 当科における甲状腺癌に対するレンバチニブ治療経験

Search this article

Abstract

<p>We retrospectively reviewed the safety and efficacy of treatment with lenvatinib for thyroid cancer. Eight patients with thyroid cancer (five with papillary carcinoma, two with medullary carcinoma, and one with squamous cell carcinoma) were analyzed. Five patients were male, and three were female. The median age was 67.8 years. Five patients were treated for recurrent disease after definitive therapy, and three were treated as primary therapy for metastatic or unresectable disease. The median overall survival was 12.9 months. The best objective responses were a partial response for six cases, stable disease for one case, and progressive disease for one case. The response rate was 75%. Common adverse events were as follows:hypertension, fatigue, palmar-plantar erythrodysesthesia syndrome, diarrhea, nausea/vomiting, and decreased platelet count. All patients experienced drug withdrawal and dose reduction. All but one patients achieved disease control at three months. At 12 months, a long-term response had been achieved by 5 patients. A rare case of thyroid squamous cell carcinoma is described.</p>

Journal

  • jibi to rinsho

    jibi to rinsho 64 (6), 228-236, 2018-11-20

    JIBI TO RINSHO KAI

Related Projects

See more

Details 詳細情報について

Report a problem

Back to top